Patients taking pazopanib for advanced renal cancer report better quality of life

the ONA take:

Two FDA-approved first-line treatments for renal cell cancer were proven to have equal benefits in patients with metastatic kidney cancer; however, the safety profile and many quality-of-life measures favored one drug over the other. A large international clinical trial led by researchers at Dana-Farber Cancer Institute found that pazopanib (Votrient) was better tolerated compared with sunitinib (Sutent). The study, sponsored by GlaxoSmithKline Pharmaceuticals, the manufacturer of pazopanib, compared the efficacy, safety, and tolerability of the two similar tyrosine kinase inhibitors. The researchers reported that clinical results were comparable, but patients taking pazopanib had fewer phone consultations with providers and fewer visits to emergency departments, which could influence cost-benefit comparisons.

Patients taking pazopanib for advanced renal cancer report better quality of life
Patients taking pazopanib for advanced renal cancer report better quality of life
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
READ FULL ARTICLE From 170.223.191.243
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs